secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009740
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected
--------------------------------------------------------------------------------

- Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.
- Vonaprument Phase 3 ARCHER II topline data for geographic atrophy expected second half of 2026; enrolled 659 patients.
- ANX1502 proof-of-concept data in cold agglutinin disease (CAD) anticipated in 2026; oral C1 inhibitor.
- Financial position funds operations into late 2027, well past anticipated key milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526009740/0001193125-26-009740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526009740/d75965d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer